Synchronous and metachronous myeloid and lymphoid tumors


Cite item

Full Text

Abstract

AIM. To determine the clinical features of multiple primary tumors (MPT) in patients with hemoblastoses, to develop treatment policy for synchronous and metachronous tumors, and to determine the impact of chemotherapy for one disease on the course and prognosis of another one. MATERIALS AND METHODS. The investigation included 20 patients with multiple primary synchronous and metachronous myeloid and lymphoid tumors, who had been followed up at the Outpatient Department of the Hematology Research Center, Ministry of Health of the Russian Federation. The distribution of patients by nosological entities was as follows: 17 (85%) patients with myeloproliferative diseases (MPDs) concurrent with lymphoproliferative diseases (LPDs) and 3 (15%) with two types of MPD. A special group comprised 3 patients who successively developed 3 malignant diseases: cancer/B-cell chronic lymphocytic leukemia (B-CLL)/Ph-positive chronic myeloid leukemia (Ph+CML); cancer/polycythemia vera (PCV)/B-CLL; cancer/essential thrombocythemia (ETC)/multiple myeloma (MM). RESULTS. The Outpatient Department of the Hematology Research Center, Ministry of Health of the Russian Federation, followed up 20 patients with synchronous and metachronous tumors in 1996 to 2013. The patients' age was 42 to 82 years (64 years). The female/male ratio was 1:1.2. Metachronous tumors were 1.5-fold higher than synchronous ones. The time to detection of secondary hemoblastosis averaged 3.3 years; the longest interval was 14 years; the mean coexistence of 2 tumors was 4.8 years (1-11 years). The total length of the follow-up was 8 years (1-19 years). Among them, there were 17 (85%) patients with 2 chronic hematologic tumors with a myeloid or lymphoid phenotype; 3 (15%) of the 20 patients had 3 malignant diseases (cancer/ B-CLL)/Ph+CML, cancer/PCV/B-CLL, cancer/ETC/MM. In the group of 17 patients, 13 (76%) were diagnosed as having Ph-negative MPDs (PCV in 4 patients, primary myelofibrosis in 4, ETC in 4, undifferentiated MPD in1) and 4 (24%) patients had Ph+CML. This patient group was found to have the following LPDs: CLL in 5 (30%), hairy cell leukemia in 1 (5%), paraproteinemic hemoblastoses in 11 (65%). MPD preceded LPD in 8 (47%) patients; the development interval between two tumors averaged 6 years (1 to 14 years). LPD preceded MPD in 3 (18%) patients; the interval averaged 5 years (2 to 17 years). MPD and LPD appeared synchronously in 6 (35%) patients. CONCLUSION. The fact that 2 malignancies or more may occur in one patient determines the need for a careful follow-up of patients with blood system diseases. The activity of one hematologic disease or another is a leading criterion for choosing a therapeutic tactic.

About the authors

A L Melikian

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: anoblood@mail.ru

T I Kolosheĭnova

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: kolosh@blood.ru

S R Goriacheva

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: svgor@blood.ru

I N Subortseva

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: soubortseva@yandex.ru

M V Vakhrusheva

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: poliklinikagnc@mail.ru

E N Kolosova

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: poliklinikagnc@mail.ru

A B Sudarikov

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: andrey@sudarikov.net

A O Abdullaev

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: adham_abdullaev@mail.ru

V N Dvirnyk

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: vdvirnyk@mail.ru

E Iu Varlamova

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: poliklinikagnc@mail.ru

A M Kovrigina

ФГБУ "Гематологический научный центр" Минздрава России, Москва

Email: kovrigina.alla@gmail.com

A G Turkina

ФГБУ "Гематологический научный центр" Минздрава России, Москва

References

  1. Петров Н.Н. Распространение злокачественных опухолей по организму. Злокачественные опухоли. Т. 1. М1947.
  2. Сторожаков Г.И., Поддубная И.В., Ковригина А.М. и др. Синхронное развитие неходжкинской лимфомы и гепатоцеллюлярной карциномы у больного хроническим гепатитом С. Экспер и клин гастроэнтерол 2008; 8: 110-114.
  3. Чиссов В.И. Первично-множественные злокачественные опухоли. Руководство для врачей. М: Медицина 2000; 336.
  4. Воробьев А.И., Абдулкадыров К.М., Туркина А.Г. и др. Диагностика и терапия хронического миелолейкоза М 2011.
  5. Цыба Н.Н., Обухова Т.Н., Капланская И.Б. и др. Сочетание двух форм хронического лейкоза и солидной опухоли у одного больного. Тер арх 2007; 10: 73-77.
  6. Hernández Sánchez M.C., García Quiroga H., Ulibarrena Redondo C., Méndez Sánchez J. A. Concurrent lymphoproliferative and myeloproliferative disorders in three patients. An Med Interna (Madrid) 2008; 25 (2): 78-80.
  7. Manoharan A., Catovsky D., Clein P. et al. Simultaneous or spontaneous occurrence of lympho- and myeloproliferative disorders: a report of four cases. Br J Haematol 1981; 48 (1): 111-116.
  8. Горячева С.Р., Двирнык В.Н., Ковригина А.М., Меликян А.М. Последовательное развитие трех злокачественных заболеваний у одной больной. В кн.: Опыт применения ингибиторов тирозинкиназы при хроническом миелолейкозе. 2013: 11-13.
  9. Гусарова Г.А., Семенова Е.А., Абдуллаев А.О. и др. Мутация Jak2 V617F у больного с Ph-позитивным хроническим миелолейкозом (ХМЛ). Мониторинг молекулярных маркеров при атипичном течении ХМЛ как основа терапевтических решений. В кн.: Опыт применения ингибиторов тирозинкиназы при хроническом миелолейкозе. 2013: 8-10.
  10. Шаркунов Н.Н., Моисеева Т.Н., Зыбунова Е.Е. и др. Успешное лечение лимфомы Ходжкина у больной Ph+-хроническим миелолейкозом. Тер арх 2012; 11: 71-74.
  11. Kramer A., Reiter A., Kruth J. et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 2007; 8: 658-660.
  12. Papageorgiou M.-V., Alexopoulou A., Kontopidou F. et al. Concomitant diagnosis of myeloproliferative neoplasm and Non-Hodgkin's lymphoma in a patient with portal vein thrombosis. Anticancer Res 2011; 31 (4): 1467-1469.
  13. Mirza I., Frantz C., Clarke G. et al. Polycytemia Vera to Chronic Myelogenous Leukemia. Arch Pathol Lab Med 2007; 131 (11): 1719-1724.
  14. Меликян А.Л., Горячева С.Р., Суборцева И.Н. и др. Первично-множественные злокачественные метахронные опухоли: рак молочной железы, В-ХЛЛ, ХМЛ у одной больной. Х Рос. конф. с междунар. уч. "Злокачественные лимфомы". Постер №57.
  15. Hauck G., Jonigk D., Kreipe H., Hussein K. Simultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms. Acta Haematologica 2013; 129: 187-196.
  16. Laurenti L. The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: A retrospective multicentric GIMEMA experience. Am J Hematol 2011; 86: 1007-1012.
  17. Baccarani M., Cortes J. Chronic Myeloid Leukemia: An update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 2009; 27 (35): 6041-6051.
  18. Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
  19. Bornhaeuser M., Mohr B., Oelschlaegel А. et al. Concurrent Jak2 (V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007; 21: 1824-1826.
  20. Kremer M., Horn T., Koch I. et al. Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol 2008; 32 (6): 928-935.
  21. Maher V.E., Gill L., Townes P.L. et al. Simultaneous chronic lymphocytic leukemia and chronic myelogenous leukemia. Evidence of a separate stem cell origin. Cancer 1993; 71 (6): 1993-1997.
  22. Zollino M., Genuardi M., Tanci P. et al. Chronic myelogenous leukemia in the course of chronic lymphocytic leukemia: evidence for an independent clonal origin. Leuk Res 1991; 15 (4): 269-273.
  23. Musolino C., Allegra A., Penna G. et al. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol 2009; 122 (1): 46-49.
  24. Mossafa H., Fourcade C., Pulic M. et al. Chronic lymphocytic leukemia associated with myelodysplastic syndrome and/or chronic myeloid leukemia: evidence for independent clonal chromosomal evolution. Leuk Lymphoma 2001; 41 (3-4): 337-341.
  25. Nieto L.H., Raya Sánchez J.M., Arguelles H.A. et al. A case of chronic lymphocytic leukemia overwhelmed by rapidly progressive idiopathic myelofibrosis. Haematologica 2000; 85 (9): 973-977.
  26. Nilsson T., Nilsson L., Lenhoff S. et al. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer 2004; 41 (3): 223-231.
  27. Orciuolo E., Fazzi R., Galimberti S. et al. Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy. Leuk Res 2006; 30 (3): 349-353.
  28. Bernasconi P., Boni M., Cavigliano P.M. et al. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea (2008) Leukemia 2002; 16 (10): 2078-2083.
  29. Malhotra J., Kremyanskaya M., Schorr E. et al. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. J Clin Lymphoma Myeloma Leuk 2014; 14 (1): 31-36.
  30. Romanenko N.A., Bessmel'tsev S.S., Udal'eva V.Iu. et al. The combination of chronic myeloid leukemia and multiple myeloma in one patient. Vopr Onkol 2013; 59 (2): 103-110.
  31. Kuroda J., Matsumoto Y., Tanaka R. et al. JAK2V617F-positive essential thrombocythemia and multiple myeloma with IgH/CCND1 gene translocation coexist, but originate from separate clones. Acta Haematol 2008; 120: 177-1781.
  32. Meerkin D., Ashkenazi Y., Gottschalk-Sabag S. et al. Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia. Cancer 1994; 73: 625-628.
  33. Barosi G., Elliott M., Canepa L. et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002; 43: 2301-2307.
  34. Quintas-Cardama A., Vaddi K., Liu P. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115: 3109-3117.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies